# Galectin Therapeutics (GALT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GALT
## Company Profile
- Ticker: GALT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.14 USD
- Market cap: 159373693.16 USD
- Last updated: 2026-09-08
## Business Overview
Galectin Therapeutics is a biotechnology company focused on fibrosis and metabolic-liver disease biology. Its story is centered on immune and fibrotic pathways in serious disease.
## Why The Stock Is Moving

As of Sep 8, 2026, GALT closed down 10.2% at $4.14. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Galectin sits in specialty biotechnology.

## Business Model

The company depends on clinical data, target validation, and the chance to build value in liver and fibrosis disease.

## Landscape Position

Galectin is a catalyst-driven liver-disease name whose stock reacts strongly to development updates.

## Future Catalysts

- Galectin’s catalysts are belapectin and fibrosis / oncology updates, with any clinical step determining whether the program still has room. The company needs a stronger human signal to keep the story alive.

## Recent News
- 2026-08-14 12:00 EST — [Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-june-30-2026-financial-results-and-provides-busine-bdbe0788) — Source: Galectin Therapeutics
- 2026-08-04 12:00 EST — [Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet](https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-conversion-of-105-8-million-in-debt-to-equity-si-ce202c56) — Source: Galectin Therapeutics
- 2026-06-23 12:00 EST — [Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension](https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-positive-type-c-meeting-with-the-fda-for-belapec-a0feb2ff) — Source: Galectin Therapeutics
- 2026-05-27 12:00 EST — [Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis](https://biopharmsignal.com/news/GALT/galectin-therapeutics-presents-new-easl-2026-oral-and-poster-analyses-demonstrat-c8e53529) — Source: Galectin Therapeutics
- 2026-05-15 12:00 EST — [Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-march-31-2026-financial-results-and-provides-busin-a4c2539c) — Source: Galectin Therapeutics